Rethinking drug safety signal detection and causality assessment in the age of AI: the risks of incomplete data and biased insights

Frontiers in Drug Safety and Regulation · Published 2025-09-16 · DOI 10.3389/fdsfr.2025.1678074

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.3389/fdsfr.2025.1678074

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Identifying regulatory outcomes of Non-interventional Post-Authorisation Safety Studies (PASS) in the European repository of studies using publicly available information · Frontiers in Drug Safety and Regulation · 2025 · Same journal
• Integrating environmental effects in the benefit-risk assessment of therapeutic products: a proposal and example for sustainable health and healthcare · Frontiers in Drug Safety and Regulation · 2025 · Same journal
• Promising treatment biomarkers in asthma · Frontiers in Drug Safety and Regulation · 2023 · Same journal
• Artificial intelligence for optimizing benefits and minimizing risks of pharmacological therapies: challenges and opportunities · Frontiers in Drug Safety and Regulation · 2024 · Same journal
• Navigating a transforming landscape: the evolving role of pharmacovigilance physicians in drug development and implications for future challenges and training requirements · Frontiers in Drug Safety and Regulation · 2023 · Same journal
• Machine learning analysis of patients’ perceptions towards generic medication in Greece: a survey-based study · Frontiers in Drug Safety and Regulation · 2024 · Same journal
• The use of observed-to-expected analyses as a signal detection tool in COVID-19 vaccine safety surveillance: lessons learned from an industry perspective · Frontiers in Drug Safety and Regulation · 2025 · Same journal
• The cutaneous mirror: leveraging drug-induced skin phenotypes as early visual risk signals for systemic toxicity, a comprehensive review · Frontiers in Drug Safety and Regulation · 2026 · Same journal
• Leveraging real-world data for safety signal detection and risk management in pre- and post-market settings · Frontiers in Drug Safety and Regulation · 2025 · Same journal
• Cohort event monitoring of safety of COVID-19 vaccines: the Italian experience of the “ilmiovaccinoCOVID19 collaborating group” · Frontiers in Drug Safety and Regulation · 2024 · Same journal